drugset / Trial / NCT01661101

Management of Myocardial Injury After Noncardiac Surgery Trial

NCT01661101

Phase 3 Completed 1754 enrolled Population Health Research Institute
RandomizedFactorialQuadruple-blindTreatment

Summary

Patients who have myocardial injury after noncardiac surgery are at a higher risk of dying than those who do not. One in 10 patients with myocardial injury will die within 30 days of surgery. This risk of death exists up to one year after myocardial injury. There are currently no treatments or guidelines available for heart injury after surgery, but there is evidence that taking a blood-thinner can prevent some of the deaths, both in the short and long-term. The purpose of this trial is to test the effect of two drugs (dabigatran and omeprazole) that may prevent mortality, major cardiovascular complications and major upper gastrointestinal bleeding in patients who have had myocardial injury after noncardiac surgery.

Timeline

Start
2013-01
Primary completion
2018-03-01
Completion
2018-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran Unknown 110 mg Oral
Subject Omeprazole Other / unclassified 20 mg

Indications